PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 151-175 of 411

  • PIK5-12d
    Cat. No.
    A23946

    PIK5-12d

    PIK5-12d is a potent PROTAC degrader targeting PIKfyve, with a DC₅₀ of 1.48 nM. It induces extensive cytoplasmic vacuolization, disrupts autophagic flux, and inhibits proliferation in multiple prostate cancer cell lines. PIK5-12d exhibits notable anti-tumor activity, supporting its use in cancer research.

    1 mg
    $225.00
    5 mg
    $480.00
    All 4 sizes
  • ARM165
    Cat. No.
    A23989

    ARM165

    ARM165 is a heterobifunctional PROTAC molecule that targets and degrades PIK3CG (PI3Kγ), effectively inhibiting the PI3Kγ-Akt signaling pathway. It exhibits potent antileukemic activity, suppressing the proliferation of acute myeloid leukemia (AML) cells with an IC₅₀ of less than 1 μM. ARM165 is a promising tool for investigating PI3Kγ-driven signaling and developing targeted therapies for leukemia.

    1 mg
    $450.00
    5 mg
    $1,350.00
    All 4 sizes
  • SY-LB-35
    Cat. No.
    A24106

    SY-LB-35

    SY-LB-35 is a potent agonist of bone morphogenetic protein (BMP) receptors, capable of activating both canonical and non-canonical signaling pathways. In the C2C12 myoblast cell line, SY-LB-35 significantly enhances cell proliferation and viability, promoting cell cycle progression by increasing the proportion of cells in the S and G2/M phases. Mechanistically, it activates the canonical Smad pathway as well as non-canonical PI3K/Akt, ERK, p38, and JNK signaling cascades. These properties make SY-LB-35 a valuable tool for studying BMP-related cellular processes and a potential therapeutic candidate for tissue regeneration and muscle repair.

    5 mg
    $59.00
    10 mg
    $101.00
    All 4 sizes
  • MTX-531
    Cat. No.
    A24175

    MTX-531

    MTX-531 is an orally active small molecule that inhibits EGFR (IC50 = 14.7 nM) and multiple PI3K isoforms, with IC50 values of 6.4 nM (PI3Kα), 233 nM (PI3Kβ), 8.3 nM (PI3Kγ), and 1.1 nM (PI3Kδ), demonstrating potent antitumor activity. Additionally, MTX-531 functions as a weak PPARγ agonist (IC50 = 2.5 µM), which may mitigate PI3K inhibitor-induced hyperglycemia.

    5 mg
    $144.00
    10 mg
    $248.00
    All 4 sizes
  • PI3K/Akt/mTOR-IN-2
    Cat. No.
    A24214

    PI3K/Akt/mTOR-IN-2

    PI3K/Akt/mTOR-IN-2 is an inhibitor of the PI3K/AKT/mTOR signaling pathway with demonstrated anticancer activity. It selectively inhibits the proliferation of MDA-MB-231 cells with an IC50 of 2.29 μM and induces cell cycle arrest and apoptosis, making it a promising candidate for cancer research.

    5 mg
    $72.00
    10 mg
    $124.00
    All 4 sizes
  • Hirsutenone
    Cat. No.
    A24234

    Hirsutenone

    Hirsutenone is a bioactive diarylheptanoid derived from Alnus species, known for its anti-inflammatory, anti-tumor-promoting, and anti-atopic dermatitis properties. It attenuates adipogenesis by directly binding to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone is a valuable compound for research related to obesity and metabolic disorders.

    1 mg
    $225.00
    5 mg
    $675.00
    All 4 sizes
  • SRX3177
    Cat. No.
    A24272

    SRX3177

    SRX3177 is a potent triple inhibitor targeting CDK4/6, PI3K, and BRD4, with IC50 values of

    5 mg
    $162.00
    10 mg
    $279.00
    All 4 sizes
  • Lipoteichoic acid
    Cat. No.
    A24481

    Lipoteichoic acid

    Lipoteichoic acid is an orally active compound with anti-inflammatory and antitumor properties. It is a key immune molecule found in Gram-positive bacteria that activates the complement system by upregulating C3 and inhibiting CD55. Lipoteichoic acid modulates macrophage autophagy via the PI3K/Akt/mTOR pathway, induces lung injury in mouse models, and inhibits melanin production.

    1 mg
    $162.00
    5 mg
    $486.00
    All 4 sizes
  • SQLE-IN-1
    Cat. No.
    A24611

    SQLE-IN-1

    SQLE-IN-1 is a potent inhibitor of squalene epoxidase (SQLE). This compound effectively suppresses the proliferation and migration of Huh7 hepatocellular carcinoma cells, while also reducing cellular cholesterol synthesis. Additionally, SQLE-IN-1 promotes the upregulation of PTEN and concurrently inhibits the PI3K/AKT signaling pathway, underscoring its potential in cancer research and therapeutic applications.

    1 mg
    $75.00
    5 mg
    $185.00
    All 6 sizes
  • Arenobufagin
    Cat. No.
    A24625

    Arenobufagin

    Arenobufagin is a natural bufadienolide that targets the PI3K/Akt/mTOR signaling pathway to induce apoptosis and autophagy in human hepatocellular carcinoma cells. It exhibits significant antineoplastic activity against both HepG2 and multidrug-resistant HepG2/ADM cell lines. Additionally, Arenobufagin inhibits VEGF-mediated angiogenesis through the suppression of VEGFR-2 signaling, making it a valuable compound for cancer research and therapeutic investigations.

    1 mg
    $40.00
    2 mg
    $60.00
    All 8 sizes
  • UCL-TRO-1938
    Cat. No.
    A24628

    UCL-TRO-1938

    UCL-TRO-1938 is a potent allosteric activator of phosphoinositide 3-kinase alpha (PI3Kα), exhibiting an EC50 value of approximately 60 μM. This compound promotes cell proliferation and demonstrates cardioprotective effects against ischemia-reperfusion injury. Additionally, UCL-TRO-1938 enhances nerve regeneration following nerve crush, making it a valuable tool in neuroprotection and regenerative medicine research.

    5 mg
    $100.00
    10 mg
    $165.00
    All 6 sizes
  • Tersolisib
    Cat. No.
    A24629

    Tersolisib

    Synonyms: STX-478; STX-478-101; LY4064809

    Tersolisib is a selective allosteric inhibitor of PI3Kα, specifically designed to target mutant forms of the enzyme. This compound exhibits significant anti-tumor activity, demonstrating robust and durable regression in various cancer models. Tersolisib is valuable in cancer research, particularly for studies focusing on PI3K pathway alterations and their therapeutic implications.

    1 mg
    $65.00
    5 mg
    $160.00
    All 6 sizes
  • Veratramine
    Cat. No.
    A24634

    Veratramine

    Synonyms: NSC17821; NSC23880

    Veratramine is a selective inhibitor of the PI3K/Akt/mTOR signaling pathway and serves as a modulator of SIGMAR1. This compound facilitates autophagic apoptosis in tumor cells, effectively induces G0/G1 cell cycle arrest, and diminishes epithelial-mesenchymal transition (EMT) markers, thereby reducing tumor migration. Additionally, Veratramine exhibits neuroprotective effects by inhibiting SIGMAR1 interactions with NMDAR and the phosphorylation of NMDAR Ser896, resulting in reduced neurological damage in neuropathy models. Its diverse biological activities make it suitable for research on liver cancer, osteosarcoma, and diabetic peripheral neuropathy.

    5 mg
    $25.00
    10 mg
    $35.00
    All 7 sizes
  • BBO-10203
    Cat. No.
    A24637

    BBO-10203

    BBO-10203 is a potent PI3Kα inhibitor that selectively and covalently binds to Cys242 in the RAS-Binding Domain. It inhibits both the GTP-bound and GDP-bound states of KRASG12C with an IC50 of 0.031 nM and an EC50 of 0.02 nM. By disrupting the interaction between RAS isoforms and PI3Kα, BBO-10203 effectively reduces pERK expression, suppresses cell growth, and induces G1 arrest and apoptosis. This compound is valuable for research into breast cancer, colorectal cancer, and non-small cell lung cancer.

    1 mg
    $1,585.00
    5 mg
    $3,380.00
    All 5 sizes
  • PI3K/Akt/CREB activator 1
    Cat. No.
    A24641

    PI3K/Akt/CREB activator 1

    PI3K/Akt/CREB activator 1 is a potent, orally active compound that stimulates the PI3K/Akt/CREB signaling pathway. This activator promotes neuronal proliferation, induces differentiation of Neuro-2a cells into neuron-like cells, and facilitates the axon-dendrite polarization in primary hippocampal neurons by upregulating brain-derived neurotrophic factor. It is particularly relevant for research into vascular dementia (VaD).

    2 mg
    $80.00
    5 mg
    $100.00
    All 6 sizes
  • PI3K/AKT-IN-1
    Cat. No.
    A24642

    PI3K/AKT-IN-1

    PI3K/AKT-IN-1 is a potent dual inhibitor of the PI3K/AKT signaling pathway, exhibiting IC50 values of 6.99 μM for PI3Kγ, 4.01 μM for PI3Kδ, and 3.36 μM for AKT. This compound demonstrates significant anticancer activity by disrupting the PI3K/AKT axis, leading to the induction of caspase-3 dependent apoptosis. It serves as a valuable tool for research in cancer biology and therapeutic development targeting the PI3K/AKT pathway.

    1 mg
    $55.00
    5 mg
    $135.00
    All 8 sizes
  • iMDK
    Cat. No.
    A24643

    iMDK

    iMDK is a potent inhibitor of phosphoinositide 3-kinase (PI3K) and midkine (MDK), a growth factor associated with tumorigenesis. This compound has demonstrated the ability to effectively suppress non-small cell lung cancer (NSCLC) growth, particularly in combination with MEK inhibitors, while exhibiting minimal toxicity to normal cells and healthy mouse models. iMDK is a valuable tool for researchers studying cancer biology and potential therapeutic strategies targeting the PI3K/MDK signaling pathway.

    1 mg
    $45.00
    5 mg
    $105.00
    All 6 sizes
  • Zovegalisib
    Cat. No.
    A24644

    Zovegalisib

    Synonyms: RLY-2608

    Zovegalisib is an orally active allosteric inhibitor that selectively targets mutant forms of PI3Kα, exhibiting significant anti-tumor activity. This compound has demonstrated efficacy in inhibiting tumor growth in PIK3CA-mutant xenograft mouse models while exhibiting minimal effects on insulin levels. It is valuable for research into targeted cancer therapies and the exploration of PI3K signaling pathways.

    1 mg
    $65.00
    5 mg
    $330.00
    All 6 sizes
  • Methyl Eugenol
    Cat. No.
    A24888

    Methyl Eugenol

    Synonyms: O-methyleugenol; eugenyl methyl ether; Eugenol Methyl ether; 4-allylveratrole

    Methyl Eugenol is an anti-insect agent primarily effective against the oriental fruit fly (Bactrocera dorsalis). In addition to its insecticidal properties, Methyl Eugenol exhibits anti-cancer and anti-inflammatory activities, making it a versatile compound for biological research. It has been shown to induce autophagy in cells and can be utilized in studies related to intestinal ischemia/reperfusion injury.

    50 mg
    $25.00
    100 mg
    $30.00
    All 8 sizes
  • ST-168
    Cat. No.
    A25325

    ST-168

    ST-168 is an orally bioavailable inhibitor of MEK and PI3K, exhibiting IC50 values of 182 nM for MEK1 and showing varying potency against PI3K isoforms with values of 69.2 nM, 41.7 nM, 1482 nM, and 2293 nM for PI3Kα, PI3Kδ, PI3Kβ, and PI3Kγ, respectively. It effectively inhibits ERK1/2 and AKT phosphorylation, inducing apoptosis in cancer cells within a 3D tumor sphere model. In vivo studies demonstrate its substantial antitumor efficacy in A375 melanoma mouse models. Additionally, ST-168 displays an improved ocular safety profile compared to conventional MEK inhibitors, evidenced by reduced caspase activation and apoptosis levels, making it a valuable tool for melanoma research.

    Out of stock

    All 3 sizes
  • 20-5,14-HEDE
    Cat. No.
    A25381

    20-5,14-HEDE

    Synonyms: WIT003

    20-5,14-HEDE is a synthetic analog of 20-HETE that primarily targets the PI3K/Akt signaling pathway. This compound exhibits significant anti-apoptotic properties and promotes cell survival, making it valuable for studies related to cellular resilience. Additionally, 20-5,14-HEDE functions as an agonist for 20-HETE, increasing intracellular calcium levels and enhancing vasoconstriction. Its multifaceted biological activities make it suitable for research in cardiovascular and cellular signaling pathways.

    1 mg
    $785.00
    5 mg
    $2,010.00
    All 3 sizes
  • Isocucurbitacin B
    Cat. No.
    A25613

    Isocucurbitacin B

    Isocucurbitacin B selectively inhibits the PI3K/AKT signaling pathways, along with the MAPK and STAT3 pathways, demonstrating notable anti-cancer properties. This natural terpenoid, derived from Pedicellus melo, effectively suppresses cancer cell proliferation, migration, and invasion. Additionally, Isocucurbitacin B induces apoptosis and facilitates G2/M phase cell cycle arrest, while altering intracellular cholesterol and pH levels, and elevating intracellular calcium levels. It serves as a valuable reagent for research applications in cancer biology, particularly in the study of glioma.

    1 mg
    $205.00
    2 mg
    $305.00
    All 6 sizes
  • PI3K-IN-7
    Cat. No.
    A25625

    PI3K-IN-7

    PI3K-IN-7 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) that effectively inhibits the phosphorylation of AKT, thereby disrupting downstream signaling pathways essential for cell survival. This compound promotes apoptosis in tumor cells while exhibiting low toxicity towards normal cells. PI3K-IN-7 is suitable for research applications focused on acute and chronic leukemia, multiple myeloma, and lymphoma.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • DFX117
    Cat. No.
    A25629

    DFX117

    DFX117 is a selective, orally active inhibitor targeting PI3Kα and c-Met tyrosine kinase. This compound effectively inhibits the PI3K/Akt/mTOR pathway, demonstrating significant antiproliferative activity against cancer cell lines such as NCI-H1975, NCI-H1993, and HCC827, with IC50 values ranging from 0.02 to 0.08 µM. DFX117 induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in A549 and NCI-H1975 cells. Additionally, DFX117 exhibits notable antitumor efficacy in murine models, making it a valuable tool for cancer research.

    Out of stock

    All 3 sizes
  • Erufosine
    Cat. No.
    A25635

    Erufosine

    Synonyms: ErPC3; Erucylphosphohomocholine

    Erufosine is a potent inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It demonstrates significant cytotoxic activity against breast cancer cell lines, specifically MCF-7 and MDA-MB-231, with IC50 values of 40.95 μM and 40.8 μM, respectively. By reducing the phosphorylation levels of PI3K (p85), Akt (PKB), and cRaf, Erufosine serves as a valuable tool in the research of breast cancer and myeloid leukemia.

    Out of stock

    All 3 sizes

Items 151-175 of 411

Added to your cart

View Cart Checkout

    Loading...